Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be we...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrisette, Taylor, Molina, Kyle C, Da Silva, Beatriz, Mueller, Scott W, Damioli, Laura, Krsak, Martin, Miller, Matthew A, Fish, Douglas N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126493/
https://www.ncbi.nlm.nih.gov/pubmed/35615295
http://dx.doi.org/10.1093/ofid/ofac028
_version_ 1784712142565408768
author Morrisette, Taylor
Molina, Kyle C
Da Silva, Beatriz
Mueller, Scott W
Damioli, Laura
Krsak, Martin
Miller, Matthew A
Fish, Douglas N
author_facet Morrisette, Taylor
Molina, Kyle C
Da Silva, Beatriz
Mueller, Scott W
Damioli, Laura
Krsak, Martin
Miller, Matthew A
Fish, Douglas N
author_sort Morrisette, Taylor
collection PubMed
description Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated.
format Online
Article
Text
id pubmed-9126493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91264932022-05-24 Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success Morrisette, Taylor Molina, Kyle C Da Silva, Beatriz Mueller, Scott W Damioli, Laura Krsak, Martin Miller, Matthew A Fish, Douglas N Open Forum Infect Dis Brief Report Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated. Oxford University Press 2022-05-23 /pmc/articles/PMC9126493/ /pubmed/35615295 http://dx.doi.org/10.1093/ofid/ofac028 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Morrisette, Taylor
Molina, Kyle C
Da Silva, Beatriz
Mueller, Scott W
Damioli, Laura
Krsak, Martin
Miller, Matthew A
Fish, Douglas N
Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title_full Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title_fullStr Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title_full_unstemmed Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title_short Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
title_sort real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126493/
https://www.ncbi.nlm.nih.gov/pubmed/35615295
http://dx.doi.org/10.1093/ofid/ofac028
work_keys_str_mv AT morrisettetaylor realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT molinakylec realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT dasilvabeatriz realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT muellerscottw realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT damiolilaura realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT krsakmartin realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT millermatthewa realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess
AT fishdouglasn realworlduseoftedizolidphosphatefor28daysormoreacaseseriesdescribingtolerabilityandclinicalsuccess

Ejemplares similares